Drug Trial Radar · NCT07700875
A Phase II Clinical Study of QR12000 Compound Tablets in Patients With Moderate to Severe Essential Hypertension
Last checked: Nov 20, 2026Latest source record: Jul 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
391
Actual
Start
Dec 29, 2022
Primary completion
Aug 20, 2023
Study completion Sep 11, 2023
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Jul 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the antihypertensive effect of QR12000 Compound Tablets with its single component, QR01019 potassium salt, and with valsartan in patients with moderate to severe essential hypertension.
Conditions
- Essential Hypertension
Interventions
QR12000 Compound Tablets 75 mgDrug
QR12000 Compound Tablets 75 mg QD
QR12000 Compound Tablets 75 mg placeboDrug
Matching placebo of QR12000 Compound Tablets 75 mg QD
QR12000 Compound Tablets 150 mgDrug
QR12000 Compound Tablets 150 mg QD
QR12000 Compound Tablets 150 mg placeboDrug
Matching placebo of QR12000 Compound Tablets 150 mg QD
QR01019 potassium salt 50 mgDrug
QR01019 potassium salt 50 mg QD
QR01019 potassium salt 50 mg placeboDrug
Matching placebo of QR01019 potassium salt 50 mg QD
Sacubitril / valsartan 200 mgDrug
Sacubitril / valsartan 200 mg QD
Sacubitril / valsartan 200 mg placeboDrug
Matching placebo of Sacubitril / valsartan 200 mg QD
Valsartan 160 mgDrug
Valsartan 160 mg QD
Valsartan 160 mg placeboDrug
Matching placebo of Valsartan 160mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 8Time frame: Baseline and week 8.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qilu Hospital of Shandong University
Jinan, Shangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.